KRCA-0008

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

KRCA-0008 is a potent, selective ALK inhibitor with IC50 of 12 nM (wt ALK).

KRCA-0008 is a potent, selective ALK inhibitor with IC50 of 12 nM (wt ALK), also is potent against various ALK mutants, including L1196M, F1174L, R1275Q, and C1156Y (IC50=5-75 nM); weakly inhibits IR (IC50=210 nM), inhibits H3122 and BaF3 EML4-ALK L1196M cell proliferation with IC50 of 80 and 68 nM, respectively; demonstrates in vivo efficacy comparable to Crizotinib in xenograft mice model, has drug-like properties without hERG concerns.

KRCA 0008;KRCA0008

Angiogenesis

ALK

ACK;ALK

Cancer

——

1472795-20-2

609.12

C30H37ClN8O4

>98% (HPLC)

10 mM in DMSO

ClC1=CN=C(NC2=CC=C(N3CCN(C(C)=O)CC3)C=C2OC)N=C1NC4=CC=C(N5CCN(C(C)=O)CC5)C=C4OC

Ethanone, 1,1'-[(5-chloro-2,4-pyrimidinediyl)bis[imino(3-methoxy-4,1-phenylene)-4,1-piperazinediyl]]bis-

(-20℃)

With Ice Pack

≥ 2 years